Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
Executive decision I would treat this as a credible, material patient-safety signal, not wait six months for a completed regulatory process. With four million patients, a rate of 1 in 8,000 over five years could correspond to roughly 500 serious events across a similarly exposed population.Read the full answer
As CEO, my overriding duty is to balance patient safety, legal/regulatory compliance, fiduciary responsibility, and long-term corporate survival. A 1-in-8,000 risk of liver failure is rare but severe, potentially fatal, and materially unexpected relative to the current label.Read the full answer